These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Ma TK; Lam YY; Tan VP; Kiernan TJ; Yan BP Pharmacol Ther; 2010 Feb; 125(2):249-59. PubMed ID: 19919843 [TBL] [Abstract][Full Text] [Related]
6. Clopidogrel-drug interactions. Bates ER; Lau WC; Angiolillo DJ J Am Coll Cardiol; 2011 Mar; 57(11):1251-63. PubMed ID: 21392639 [TBL] [Abstract][Full Text] [Related]
7. Do the association of cytochrome P450 interacting drugs, influence clopidogrel efficacity? Tho A; Mihoubi A Am Heart J; 2009 Jul; 158(1):e7; author reply e9. PubMed ID: 19540383 [No Abstract] [Full Text] [Related]
8. Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel. Petersen KU Arzneimittelforschung; 2009; 59(5):213-27. PubMed ID: 19537521 [TBL] [Abstract][Full Text] [Related]
9. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009 [TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias WL; Braunwald E; Sabatine MS Circulation; 2009 May; 119(19):2553-60. PubMed ID: 19414633 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways. Máchal J; Hlinomaz O Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111 [TBL] [Abstract][Full Text] [Related]
12. Clinical use of clopidogrel. Sarafoff N; Byrne RA; Sibbing D Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411 [TBL] [Abstract][Full Text] [Related]
13. Thienopyridines and statins: assessing a potential drug-drug interaction. Neubauer H; Mügge A Curr Pharm Des; 2006; 12(10):1271-80. PubMed ID: 16611111 [TBL] [Abstract][Full Text] [Related]
14. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Ma TK; Lam YY; Tan VP; Yan BP Br J Clin Pharmacol; 2011 Oct; 72(4):697-706. PubMed ID: 21352268 [TBL] [Abstract][Full Text] [Related]
16. [Interaction between clopidogrel and proton pump inhibitors]. Harmsze AM; de Boer A; Boot H; Deneer VH; Heringa M; Mol PG; Schalekamp T; Verduijn MM; Verheugt FW; le Comte M Ned Tijdschr Geneeskd; 2011; 155(28):A2442. PubMed ID: 21771377 [TBL] [Abstract][Full Text] [Related]
17. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616 [TBL] [Abstract][Full Text] [Related]
18. Clopidogrel and proton pump inhibitors--where do we stand in 2012? Drepper MD; Spahr L; Frossard JL World J Gastroenterol; 2012 May; 18(18):2161-71. PubMed ID: 22611308 [TBL] [Abstract][Full Text] [Related]
19. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Focks JJ; Brouwer MA; van Oijen MG; Lanas A; Bhatt DL; Verheugt FW Heart; 2013 Apr; 99(8):520-7. PubMed ID: 22851683 [TBL] [Abstract][Full Text] [Related]
20. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians. Tran M; Tafreshi J; Pai RG J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):326-37. PubMed ID: 20938037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]